239 related articles for article (PubMed ID: 28178675)
21. Low cytoplasmic and nuclear KPNA2 expression in radiotherapy-treated head and neck squamous cell cancer is associated with an adverse outcome.
Erben PB; Brunner K; Hecht M; Haderlein M; Büttner-Herold M; Agaimy A; Fietkau R; Hartmann A; Distel LV
Int J Clin Exp Pathol; 2015; 8(12):15814-24. PubMed ID: 26884852
[TBL] [Abstract][Full Text] [Related]
22. Intrahepatic Cholangiocarcinoma With Extrahepatic Metastasis and High Tumor Mutation Burden: Case of Complete Pathological Response to Cisplatin/Gemcitabine/Pembrolizumab.
Robinson MD; Wheatley R; Foster L; Jamdar S; Siriwardena AK; Lamarca A; Hubner R; Valle JW; McNamara MG
JCO Precis Oncol; 2024 Apr; 8():e2300572. PubMed ID: 38662981
[No Abstract] [Full Text] [Related]
23. High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy.
Quintavalle C; Burmeister K; Piscuoglio S; Quagliata L; Karamitopoulou E; Sepe R; Fusco A; Terracciano LM; Andersen JB; Pallante P; Matter MS
Mol Carcinog; 2017 Sep; 56(9):2146-2157. PubMed ID: 28467612
[TBL] [Abstract][Full Text] [Related]
24. Aberrant expression of KPNA2 is associated with a poor prognosis and contributes to OCT4 nuclear transportation in bladder cancer.
Zhou J; Dong D; Cheng R; Wang Y; Jiang S; Zhu Y; Fan L; Mao X; Gui Y; Li Z; Li X; Shi B
Oncotarget; 2016 Nov; 7(45):72767-72776. PubMed ID: 27611951
[TBL] [Abstract][Full Text] [Related]
25. Karyopherin Alpha 2 Is an Adverse Prognostic Factor in Clear-Cell and Papillary Renal-Cell Carcinoma.
Müller T; Tolkach Y; Stahl D; Steiner S; Hauser S; Ellinger J; Rabien A; Ralla B; Jung K; Stephan C; Kristiansen G
Clin Genitourin Cancer; 2019 Feb; 17(1):e167-e175. PubMed ID: 30448104
[TBL] [Abstract][Full Text] [Related]
26. Stathmin1 regulates p27 expression, proliferation and drug resistance, resulting in poor clinical prognosis in cholangiocarcinoma.
Watanabe A; Suzuki H; Yokobori T; Tsukagoshi M; Altan B; Kubo N; Suzuki S; Araki K; Wada S; Kashiwabara K; Hosouchi Y; Kuwano H
Cancer Sci; 2014 Jun; 105(6):690-6. PubMed ID: 24708177
[TBL] [Abstract][Full Text] [Related]
27. Aberrant expression of nuclear KPNA2 is correlated with early recurrence and poor prognosis in patients with small hepatocellular carcinoma after hepatectomy.
Jiang P; Tang Y; He L; Tang H; Liang M; Mai C; Hu L; Hong J
Med Oncol; 2014 Aug; 31(8):131. PubMed ID: 25031071
[TBL] [Abstract][Full Text] [Related]
28. The DNA index as a prognostic tool in hilar cholangiocarcinoma.
Kamphues C; Al-Abadi N; Bova R; Rademacher S; Al-Abadi H; Klauschen F; Bahra M; Neuhaus P; Pratschke J; Seehofer D
J Surg Oncol; 2015 Aug; 112(2):214-8. PubMed ID: 26220797
[TBL] [Abstract][Full Text] [Related]
29. Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology.
Borbath I; Ceratti A; Verslype C; Demols A; Delaunoit T; Laurent S; Deleporte A; Vergauwe P; Van Maanen A; Sempoux C; Van Cutsem E; Van Laethem JL;
Ann Oncol; 2013 Nov; 24(11):2824-9. PubMed ID: 23975665
[TBL] [Abstract][Full Text] [Related]
30. Downregulation of KPNA2 in non-small-cell lung cancer is associated with Oct4 expression.
Li XL; Jia LL; Shi MM; Li X; Li ZH; Li HF; Wang EH; Jia XS
J Transl Med; 2013 Sep; 11():232. PubMed ID: 24070213
[TBL] [Abstract][Full Text] [Related]
31. KPNA2 promotes cell proliferation and tumorigenicity in epithelial ovarian carcinoma through upregulation of c-Myc and downregulation of FOXO3a.
Huang L; Wang HY; Li JD; Wang JH; Zhou Y; Luo RZ; Yun JP; Zhang Y; Jia WH; Zheng M
Cell Death Dis; 2013 Aug; 4(8):e745. PubMed ID: 23907459
[TBL] [Abstract][Full Text] [Related]
32. The Upregulation of OCT4 in Acidic Extracellular pH is Associated with Gemcitabine Resistance in Cholangiocarcinoma Cell Lines.
Choodetwattana P; Proungvitaya S; Jearanaikoon P; Limpaiboon T
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2745-2748. PubMed ID: 31554372
[TBL] [Abstract][Full Text] [Related]
33. Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy.
Sasaki H; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
Br J Cancer; 2014 Sep; 111(7):1275-84. PubMed ID: 25032731
[TBL] [Abstract][Full Text] [Related]
34. Identification of Homer1 as a potential prognostic marker for intrahepatic cholangiocarcinoma.
Wu SY; Yu MX; Li XG; Xu SF; Shen J; Sun Z; Zhou X; Chen XZ; Tu JC
Asian Pac J Cancer Prev; 2014; 15(7):3299-304. PubMed ID: 24815486
[TBL] [Abstract][Full Text] [Related]
35. Increased Nuclear Transporter KPNA2 Contributes to Tumor Immune Evasion by Enhancing PD-L1 Expression in PDAC.
Zhou KX; Huang S; Hu LP; Zhang XL; Qin WT; Zhang YL; Yao LL; Yu Y; Zhou YQ; Zhu L; Ji J; Zhang ZG
J Immunol Res; 2021; 2021():6694392. PubMed ID: 33728352
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-21 regulates the invasion and metastasis in cholangiocarcinoma and may be a potential biomarker for cancer prognosis.
Huang Q; Liu L; Liu CH; You H; Shao F; Xie F; Lin XS; Hu SY; Zhang CH
Asian Pac J Cancer Prev; 2013; 14(2):829-34. PubMed ID: 23621247
[TBL] [Abstract][Full Text] [Related]
37. BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma.
Parasramka M; Yan IK; Wang X; Nguyen P; Matsuda A; Maji S; Foye C; Asmann Y; Patel T
Mol Cancer; 2017 Jan; 16(1):22. PubMed ID: 28122578
[TBL] [Abstract][Full Text] [Related]
38. High expression of KPNA2 defines poor prognosis in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy.
Shi B; Su B; Fang D; Tang Y; Xiong G; Guo Z; He Q; Yang X; Zhao W; Guo Y; Li X; Zhou L
BMC Cancer; 2015 May; 15():380. PubMed ID: 25956057
[TBL] [Abstract][Full Text] [Related]
39. Nuclear transport receptor karyopherin-α2 promotes malignant breast cancer phenotypes in vitro.
Noetzel E; Rose M; Bornemann J; Gajewski M; Knüchel R; Dahl E
Oncogene; 2012 Apr; 31(16):2101-14. PubMed ID: 21909132
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
